We utilized lentivirally delivered CRISPR-Cas9 to knock out TIAM1 in cultures of five CDX models classified as SCLC-A (Simpson et al., 2020); in each case this significantly decreased cell viability (Figure 2A). This evidence concerns the gene TIAM1 and small cell lung carcinoma.